Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 22 | 921 | 37% |
| 2020 | 13 | 667 | 40% |
| 2021 | 18 | 684 | 43% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 77% of the cases CMS names in Washington; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 46 | 2,550−2.4%/yr | −2.4%/yr | 0.7 | 0% | 2,560 in 2030+0.1%/yr |
| Arizona | 21 | 884 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 30 | 2,051−12%/yr | −12%/yr | 2.80.5× | 19% | 1,780 in 2030−2.4%/yr |
| Peripheral arterial intervention |
Carotid revascularization in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
| ≈ 670 |
| – |
| 2026 est. | ≈ 680 | – |
| 2022 | 17 | 702 | 46% |
| 2023 | 16 | 682 | 50% |
| 2024 | 15 | 658 | 54% |
| 2025 from claims | – | 671 543–788 | 54% |
| 2026 forecast | – | 680 533–854 | 54% |
| 2027 forecast | – | 681 505–900 | 55% |
| 2028 forecast | – | 682 483–941 | 56% |
| 2029 forecast | – | 682 464–978 | 57% |
| 2030 forecast | – | 683 447–1,013 | 57% |
In 2025, 100% inpatient hospital.
| −3%/yr |
| 1.2 |
| 0% |
| 1,070 in 2030+3.3%/yr |
| Oregon | 8 | 425−4.9%/yr | −4.9%/yr | 1.0 | 0% | 460 in 2030+1.4%/yr |
| Nevada | 11 | 315−0.4%/yr | −0.4%/yr | 1.1 | 0% | 610 in 2030+11%/yr |
| Colorado | 5 | 302−7.5%/yr | −7.5%/yr | 0.6 | 0% | 280 in 2030−1.5%/yr |
| Idaho | 7 | 243+15%/yr | +15%/yr | 1.2 | 0% | 590 in 2030+16%/yr |
| Utah | 2 | 170−2.8%/yr | −2.8%/yr | 0.8 | 0% | 110 in 2030−6.4%/yr |
| Montana | 4 | 162−1.2%/yr | −1.2%/yr | 0.8 | 0% | 170 in 2030+1.3%/yr |
| New Mexico | 1 | 111−8.3%/yr | −8.3%/yr | 0.5 | 0% | 150 in 2030+5.6%/yr |
| 15 |
| 2,037−9%/yr |
| −9%/yr |
| 2.50.5× |
| 14% |
| 2,490 in 2030+3.4%/yr |
| Superficial venous ablation | 7 | 779−7.1%/yr | −7.1%/yr | 1.00.2× | 83% | 860 in 2030+1.7%/yr |
| Thrombectomy, IVC filters & venous stents | 3 | 587+1.3%/yr | +1.3%/yr | 0.80.6× | 0% | 1,070 in 2030+11%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 302−6.6%/yr | −6.6%/yr | 0.41.2× | 0% | 230 in 2030−4.4%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Inspiremd leads with 43% of company spending on these surgeons in 2025, +43 pts on 2024.
In 2025, 5 companies reported engagement with Washington’s surgeons worth $6,785 in consulting, speaking, meals and travel tied to these products, about $452 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.